SCHEDULE: JPMorgan Chase Reports 4.0% Stake in Radiopharm Theranostics

JPMorgan Chase & Co. has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in Radiopharm Theranostics Limited as of December 31, 2025.

Summary

• JPMorgan Chase & Co. beneficially owns 145,679,951 ordinary shares of Radiopharm Theranostics Limited, represented by American Depositary Shares.
• This ownership represents 4.0% of the class of securities.
• JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 145,679,951 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previous beneficial ownership report.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company's operational or financial performance.

Positives

• The continued presence of a major financial institution, JPMorgan Chase & Co., as a beneficial owner of Radiopharm Theranostics Limited's shares.

Negatives

• No explicit negative information regarding the issuer or the investment is provided in this beneficial ownership disclosure.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

Radiopharm Theranostics Limited operates in the radiopharmaceutical and theranostics industry, focusing on developing targeted therapies and diagnostics. This filing reflects institutional investment activity by JPMorgan Chase & Co., a global financial services firm, within the broader healthcare and biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake.
• Investors: Offers insight into institutional interest in Radiopharm Theranostics.

Key Dates

Keywords

Radiopharm Theranostics, JPMorgan Chase, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Institutional Investment, Q79455103